Find a Clinical Trial

Takeda footprint

A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants

0-1

Learn more

Gemini 1

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio^®) in participants with relapsing forms of multiple sclerosis

18-55

Learn more

Hercules

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis

18-60

Learn more

PERSEUS

A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis

18-55

Learn more

TAP Block and minimally invasive hysterectomy for pain control

A randomized, controlled, observer-blinded pilot trial of laparoscopic large volume, multisite transversus abdominal plane (TAP) block with liposomal bupivacaine in patients undergoing minimally invasive hysterectomy for endometrial cancer

18-80

Learn more

The Connection study

A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing enterocolitis

No minimum age

Learn more

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

EA3132 - Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

18+

Learn more

Remodel-2

Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis

18-55

Learn more

GO MOMS

Glycemic Outcomes and Metabolic Observations in Mothers and Offspring

18+

Learn more

MAMMA Study

Maternal Metabolic Mediators of infant Adiposity (MaMMA)

18-45

Learn more